CMRX: Chimerix, Inc. Stock

by  •  • Comments Off on CMRX: Chimerix, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 80.83
Enterprise Value ($M) 57.18
Book Value ($M) 135.78
Book Value / Share 1.51
Price / Book 0.60
NCAV ($M) 118.01
NCAV / Share 1.31
Price / NCAV 0.68

Profitability (mra)
Return on Invested Capital (ROIC) -0.61
Return on Assets (ROA) -0.37
Return on Equity (ROE) -0.40

Liquidity (mrq)
Quick Ratio 6.33
Current Ratio 6.33

Balance Sheet (mrq) ($M)
Current Assets 140.90
Assets 158.67
Liabilities 22.89
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Ra Capital Management, L.p. 9.90 35.35
02-12 13G/A Rubric Capital Management LP 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 243,995 677,663 36.01
2024-11-14 58,278 320,618 18.18
2024-11-13 55,892 235,477 23.74
2024-11-12 55,201 214,126 25.78
2024-11-11 54,569 336,710 16.21

(click for more detail)

Similar Companies
CHRS – Coherus BioSciences, Inc. CLSD – Clearside Biomedical, Inc.
CLYM – Climb Bio, Inc. CRMD – CorMedix Inc.
CRON – Cronos Group Inc.


Financial data and stock pages provided by
Fintel.io